• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Process for transforming an essential oil, essential oil fraction thus obtained, combinations comprising the essential fraction thus obtained and an antibiotic or an antifungal and use as a medicament, in particular, use in the prevention or treatment of infectious diseases of bacterial or fungal origin.
    公开号:BE1027762B1
    申请号:E20205880
    申请日:2020-12-04
    公开日:2021-10-11
    发明作者:Ribeiro Sofia Oliveira；Florence Souard；Caroline Stévigny；Abdesselam Zhiri；Dominique Baudoux
    申请人:Univ Grenoble Alpes；Pranarom Int S A；Centre Nat Rech Scient；Univ Bruxelles；
    IPC主号:
    专利说明:

    TECHNICAL FIELD The present invention provides a process for transforming an essential oil (ET), the essential oil fraction thus obtained and its use as a medicament, in particular its use in the prevention or the treatment of infectious diseases of bacterial or fungal origin. The present invention further provides combinations comprising the essential oil fraction obtained according to the process of the present invention with an antibiotic or an antifungal as well as the uses of these combinations as a medicament, in particular their use in the prevention or the treatment of infectious diseases of bacterial or fungal origin.
    Technological background According to the European and French pharmacopoeias, an essential oil (ET) is defined as "an odorous product, generally of complex composition, obtained from a botanically defined raw material, either by steam stripping of water, either by dry distillation or by a suitable mechanical process without heating. EO is most often separated from the aqueous phase by a physical process that does not result in a significant change in its composition ".
    This definition is also adopted by AFNOR (French Association for Standardization) and ISO (International Organization for Standardization) standards, as well as by VANSM (National Agency for the Safety of Medicines and Health Products) and international bodies.
    Most essential oils are obtained by steam distillation. This process is by far the most widespread, as it is suitable for most plants and it is the method validated by the majority of pharmacopoeias. The goal is to wash away the most volatile constituents with the water vapor. The steam destroys the structure of plant cells, releases the molecules contained and entrains the most volatile molecules, separating them from the cellulosic substrate. The steam, charged with the essence of the distilled raw material, condenses in the condenser of a still before being collected in a settling vessel. The parts insoluble in the condensation water are decanted to obtain the essential oil.
    The vegetable kingdom counts several hundreds of thousands of species and 4000 of them manufacture aromatic essences; of which only a few hundred in sufficient quantity to be able to extract them.
    The conservation of essential oils is legally authorized for a period of 5 years. In addition, the essences obtained by cold expression of citrus can only be kept for 3 years.
    Essential oils can be used internally, externally or from the air. Administered internally, essential oils are sometimes irritating to the mucous membranes, they are generally mixed with vegetable oil, honey, bread crumbs or a neutral support because they do not dilute in water . In pharmacies, it is possible to buy oleocapsule-type preparations (with a base of vegetable oil and gastro-resistant capsules) as well as preparations in the form of capsules and suppositories. Vegetable oil or essential oil can enter the body through the skin (external route). In this case, it is then mixed with a vegetable massage oil or with a wax, an ointment, a cream or a body milk. Finally, the dry or wet diffusion of essential oils diffused in the air is also used.
    An essential oil can contain up to several hundred different molecules, many of which have special properties. For example, the essential oil of clary sage (Salvia sclarea), generally contains 250 different molecules. These molecules are grouped into several “biochemical families”: ketones, acids, aldehydes, alcohols, esters, ethers, sesquiterpenes, monoterpenes, aromatic oxides, hydrocarbons, phenols. This chemical "identity card" of the essential oil reflects its properties and differs according to its species or subspecies, its geographical origin, its producing organ, the nature of the soil, the altitude, the duration. sunshine and its plant environment. Many essential oils have different chemotypes.
    The use of essential oils for therapeutic purposes is called aromatherapy. This is an area of herbal medicine that is gaining momentum in the health field as a complementary therapy. Essential oils have already demonstrated, often in vitro, antiseptic, antibacterial, immuno-stimulating, decongestant, soothing, anti-spasmodic, stimulating or even anti-inflammatory effects.
    The antibacterial action (clean or combinatorial) of essential oils is of particular interest in view of resistance to antibiotic therapy, a major public health problem. Antibiotics have significantly reduced mortality associated with infectious diseases during the 20th century. The remarkable effectiveness of antibiotics has motivated their massive and repeated use in human and animal health. However, their massive and repeated use has led to the emergence of resistant bacterial strains. Punctual at the start, this resistance has become massive and worrying. Some strains are multi-resistant, that is, resistant to several antibiotics, from the same family or from different families. This phenomenon,
    constantly increasing, health experts are in a therapeutic impasse: they no longer have solutions to fight infection.
    It is known from the state of the art that EOs have antibacterial properties. For example, document DE202007015195U1 discloses that linalool, a compound of the essential oil of coriander separated by column chromatography after extraction by steam distillation from seeds, has antimicrobial activity against S aureus (own activity) as well as anti-inflammatory properties.
    The association of essential oil compounds with an antibiotic also seems to be of some interest because some of these compounds would make it possible to sensitize bacterial strains resistant to the antibiotic. For example, WO2006 / 120494A1 evaluated the sensitization of K. pneumoniae to amoxicillin by carveol. The results show that mice treated with carveol alone show a similar survival percentage to untreated mice and mice treated only with amoxicillin. On the contrary, the combination of carveol and amoxicillin protects the treated mice. According to this document, the carveol can be obtained from an essential oil or synthesized = chemically.
    Likewise, document WO2017 / 209588A2 discloses a pharmaceutical composition comprising 1,8-cineol and amoxicillin. According to this document, 1,8-cineol potentiates the effect of amoxicillin and sensitizes strains of bacteria, E.coli and K. pneumoniae, which are initially resistant. The cineol used in document WO2017 / 209588A2 is commercial cineol. This document mentions that cineol can be extracted from certain eucalyptus, rosemary, mugwort, wormwood, laurel, sage, basil and camphor tree.
    Unfortunately, the antibacterial compositions based on essential oils which currently exist, in particular the antibacterial compositions of documents DE202007015195U1, WO2006 / 120494A1 and WO2017 / 209588A2 have limitations. In particular, it is still necessary to increase the antimicrobial activity of compositions based on essential oils, against an acceptable number of bacterial and fungal strains. Furthermore, it is also necessary to develop new compositions based on essential oils which make it possible to further increase the potentiating effect of antimicrobial agents, such as antibiotics or antifungals. Description of the invention The invention makes it possible to resolve the drawbacks of the state of the art by providing a process for transforming an essential oil which results in obtaining a transformed essential oil, corresponding to the non-fraction. evaporated from essential oil. The essential oil transformed by the method according to the invention has an improved antibacterial action compared to an untransformed essential oil, has its own activity and a combinatorial activity (in combination with different antibiotics) and has a broad-spectrum antibacterial action but also antifungal. To solve this problem, a process for transforming an essential oil is provided according to the invention, comprising: - providing an essential oil previously extracted; - evaporate a fraction between 7 and 90% of the essential oil; and - obtain a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil, characterized in that the evaporation is carried out for at least 2 h, under a pressure less than or equal to 500 mbar and at a temperature between 40 and 100 ° C. In a preferred embodiment of the invention, an ET refers to an ET as defined according to the European and French pharmacopoeias, namely defined as an odorous product, generally of complex composition, obtained from a plant raw material botanically defined, either by stripping with water vapor, or by dry distillation, or by a suitable mechanical process without heating. EO is most often separated from the aqueous phase by a physical process that does not result in any significant change in its composition.
    According to a particular embodiment of the invention, EO is an odorous product obtained from a botanically defined raw material, either by entrainment with water vapor, or by dry distillation, or by a mechanical process. suitable without heating. Preferably, HE according to the invention is obtained by stripping with water vapor.
    Preferably, the EO according to the invention is not obtained by a method other than distillation or cold pressing, for example, is not obtained by extraction with a solvent, by extraction by supercritical fluid, by double distillation or by simultaneous distillation and extraction.
    In the context of the present invention, all quantities defined in percentages (%) refer to volume percentages (% volume,% volume / volume,% v / v), unless the context clearly indicates otherwise. . It will therefore be clear to those skilled in the art, for example, that the evaporation of 7% of EO means that 7% of the initial volume of EO has evaporated, while 93% of the initial volume of EO is not is not evaporated. Still according to this example, the transformed EO obtained by the process according to the invention therefore corresponds to the fraction of the EO that has not evaporated, namely 93% of the initial volume of EO. Likewise, evaporation of 90% EO means that 90% of the initial volume of EO has evaporated, while 10% of the initial volume of EO has not evaporated. Still according to this example, the transformed EO obtained by the process according to the invention therefore corresponds to the fraction of the EO that has not evaporated, namely 10% of the initial volume of EO.
    The inventors have surprisingly observed that the process according to the invention makes it possible to obtain a transformed essential oil which exhibits improved antibacterial and antifungal activity. Furthermore, the essential oil transformed by the process according to the invention can be used alone or in combination with an antibiotic, and is effective against different types of bacteria and - fungi.
    In the context of the present invention, self-activity refers to the antimicrobial activity exerted by the HE itself. Self-activity can, for example, be assessed simply by measuring the MIC (minimum inhibitory concentration), which is the smallest concentration sufficient to inhibit, in vitro, the growth of a bacterial strain, after treatment of different bacterial strains with different EOs transformed or not according to the method of the invention.
    It was observed that the EOs transformed according to the method of the invention exhibit an improved inherent activity, namely a decrease in the MIC, on various bacterial strains compared to an EO not transformed according to the method of the invention. For example, AJowan EO and lavender stoechade EO transformed according to the method of the invention exhibit at least twice the activity on at least 3 bacterial strains.
    Combinatorial activity refers to the synergistic interaction observed between transformed EO and an antimicrobial agent (which is not part of the essential oil). The combined activity can be assessed by the microdilution method. For example, by a 96-well plate microdilution method where the products alone and / or combined are diluted by two, starting from an initial concentration of the order of 1000 pg / ml. By this method the MIC is determined. Improvement in activity is observed when the MIC of the combination of an antibiotic with the essential oil, whether or not transformed, is lower than that of the antibiotic alone. For example, if the MIC of the antibiotic alone is 4 µg / ml and the value obtained in combinatorial activity is 0.5 µg / ml, there is an improvement in the activity of 8 x the activity of the antibiotic alone. The greater the decrease in the MIC, the lower the concentration needed - of antibiotic when combined with EO. The more the MIC is reduced, the more the activity of the antibiotic against the bacterial strain is potentiated. By decreasing the concentrations of the essential oil below its MIC it is likely that we have non-toxic values.
    In particular, the inventors observed an improved combinatorial activity, namely a decrease in the MIC observed with the combination when compared to that observed with the antibiotic alone when the bacteria are treated with different EOs transformed according to the method of the invention. . For example, EO of ajwain (Trachyspermum ammi), HEV of German chamomile (Matricaria recutita), EO of lemongrass (Cymbopogon citratus) and HEV of lavender stoechade (Lavandula stoechas), normally sensitize 3 bacterial strains resistant to several antibiotics, when they are transformed by the process according to the invention. Preferably the evaporation is between 10 and 90%, preferably between 20 and 75%, still preferably between 20 and 50%, even more preferably between 30 and 50%, for example around 45% of the oil essential. In fact, it was observed that the specific and combinatorial activity was improved in an increasing manner as a function of the percentage of evaporation of the EO transformed according to the process of the invention. For example, in combinatorial activity with Penicillin V, HE of compact oregano (Origanum compactum) transformed according to the method of the invention shows, on the strain S. aureus LMG 15975, a MIC of 0.125 μg / ml for evaporation. of about 16% and decreases at a MIC of 0.03 µg / ml for an evaporation of about 27.5%. In its own activity, in the case of an EO of lavender stoechade transformed according to the invention, the MICs calculated for the S. aureus LMG 8064 strain decrease between HEV not transformed and transformed according to the invention, but also decrease by half when evaporation goes from 19 to 24% and again half when evaporation goes from 24 to 41.5%.
    In a preferred embodiment of the invention, the method according to the invention comprises the steps of providing an essential oil previously extracted, evaporating between 10 and 90% of the essential oil, and obtaining a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil. Still preferably, the process according to the invention comprises the steps of providing an essential oil previously extracted, evaporating between 20 and 75% of the essential oil, and obtaining a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil. essential oil. Even more preferably, the process according to the invention comprises the steps of providing an essential oil previously extracted, evaporating between 20 and 50% of the essential oil, and obtaining a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil. 'essential oil. Even more preferably, the process according to the invention comprises the steps of providing an essential oil previously extracted, evaporating between 30 and 50% of the essential oil, and obtaining a transformed essential oil comprising the recovery of the non-evaporated fraction. essential oil. For example, the process according to the invention comprises the steps of providing an essential oil previously extracted, evaporating approximately 45% of the essential oil, and obtaining a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil. .
    Advantageously, the evaporation is carried out for a period of between 2 and 360 h, preferably between 2 and 240 h, preferably between 3 and 96 h, more preferably between 18 and 96 h, even more preferably between 24 and 96 hours, for example for a period of approximately 72 hours. The percentage of evaporation will, in particular, depend on the duration of evaporation and the volatility of each EO studied. For example, for a low volatile EO, such as palmarosa EO (Cymbopogon martinii var. Motia), a decrease in the MIC is already observed after 3 hours.
    In a particular embodiment of the invention, the evaporation is carried out under a pressure less than or equal to 300 mbar, preferably less than or equal to 150 mbar, even more preferably less than or equal to 100 mbar, even more preferably between 25 and 75 mbar, for example about 60 mbar.
    Preferably, the evaporation is carried out at a temperature between 30 and 100 ° C, preferably between 30 and 70 ° C, preferably between 35 and 60 ° C, more preferably between 40 and 60 ° C, for example at a temperature of about 40 ° C.
    Advantageously, the evaporation is between 7 and 90% and is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar, at a temperature between 35 and 60 ° C. Preferably, the evaporation is between 10 and 90% and is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar, at a temperature between 35 and 60 ° C. Preferably, the evaporation is between 20 and 75% and is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar, at a temperature between 35 and 60 ° C. Even more preferably, the evaporation is between 20 and 50% and is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar, at a temperature between 35 and 60 ° C. Even more preferably, the evaporation is between 30 and 50% and is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar, at a temperature between 35 and 60 ° C.
    According to a preferred mode of the invention, the essential oil extracted beforehand is evaporated in the presence of a solution comprising a solvent chosen from hydrocarbons such as chloroform, dichloromethane, n-hexane, cyclohexane or petroleum ether. ; ethers such as diethyl ether; esters such as ethyl acetate; ketones such as acetone; alcohols such as methanol,
    ethanol or isopropanol; and their mixtures. According to this particular mode of the invention, the solution comprising the solvent helps evaporation of the HE. It is added before evaporation and is substantially completely evaporated during the evaporation of a fraction of the EO.
    Preferably, the solution comprising a solvent is a hydro-alcoholic mixture, the alcohol being present in an amount of at least 50%.
    Advantageously, the evaporation is carried out with stirring, preferably with stirring between 20 and 300 rotations / minute, preferably between 200 and 300 rotations / minute.
    In a preferred embodiment of the invention, the essential oil is extracted beforehand from a plant selected from the group consisting of ajwain (Trachyspermum ammi), basil, for example exotic basil (Ocimum basilicum ssp basilicum) , chamomile, e.g. German chamomile (Matricaria recutita), cinnamon, e.g. Chinese cinnamon (Cinnamomum cassia), coriander, e.g. leaf coriander (Coriandrum sativum), clove tree (Eugenia caryophyllus) , lavender, for example lavender stoechade (Lavandula stoechas), lemongrass (Cymbopogon - citratus), oregano, for example compact oregano (Origanum compactum), palmarosa (Cymbopogon martinii var. motia), and their mixtures.
    In a particular embodiment, the chamomile is German chamomile, the cinnamon is Chinese cinnamon, the lavender is stoechade lavender. In a preferred embodiment of the invention, the essential oil is previously extracted from lavender stoechade or compact oregano, preferably the essential oil is previously extracted from lavender stoechade. Indeed, the inventors observed that the antibacterial action was particularly effective when the plant from which the EO is extracted and then transformed according to the process of the invention was compact oregano or lavender stoechade, the results still being senior with lavender stoechade.
    Preferably, the essential oil is first extracted from the lavender stoechade and in that the evaporation is carried out for a period of between 24 and 96 h, under a pressure of between 25 and 75 mbar and at a temperature of between 40 and 60 ° C. The inventors have, indeed, observed that the antibacterial action was particularly improved when the EO was extracted from the lavender stoechade and transformed according to the process of the invention under these particular parameters.
    Another object of the invention is an essential oil fraction obtainable by the transformation process according to the invention. The essential oil fraction according to the invention corresponds to the non-evaporated fraction of the essential oil obtained by a transformation according to the process of the invention. The HE is first extracted beforehand. The HEV extraction methods can be any method of HE extraction known to those skilled in the art. Preferably, the methods for extracting the EO are those which make it possible to obtain an EO as defined according to the European and French pharmacopoeias, namely by distillation by entrainment with water vapor, by dry distillation or by a appropriate mechanical process without heating. In particular, HE is extracted by distillation by entrainment with water vapor. Once the EO has been extracted, an evaporation of a fraction between 7 and 90% of the EO is carried out for at least 2 h, under a pressure less than or equal to 500 mbar and at a temperature between 40 and 100 ° vs. The essential EO thus transformed comprises the non-evaporated fraction of the EO.
    The evaporated fraction of EO corresponds to a percentage between 7 and 90% of EO and the fraction of EO according to the invention, namely the non-evaporated fraction of EO obtained by the process according to the invention. corresponds to a percentage between 10 and 93% of the extracted HE. An EO fraction according to the invention, namely the fraction of non-evaporated EO corresponding to a percentage between 10 and 93% of the EO has its own and / or combinatorial activity which is improved.
    Preferably, the fraction of the non-evaporated EO according to the invention corresponds to a percentage between 10 and 90%, preferably between 25 and 80%, still preferably between 50 and 80%, even more preferably between 50 and 70% , most preferably about 55% of the EO. Indeed, it has been observed that the fraction of non-evaporated EO according to the invention exhibits an antibacterial activity which improves proportionally with the decrease in the percentage of the fraction of non-evaporated EO according to the invention.
    In a preferred embodiment of the invention, the non-evaporated fraction of EO according to the invention is obtained from a plant selected from the group consisting of ajwain, basil, chamomile, cinnamon, coriander, clove, lavender, lemongrass, oregano, palmarosa, and mixtures thereof.
    In a particular embodiment, the chamomile is German chamomile, the cinnamon is Chinese cinnamon, the lavender is stoechade lavender.
    In a preferred embodiment of the invention, the non-evaporated fraction of EO according to the invention is obtained from an essential oil previously extracted from lavender stoechade or compact oregano, preferably the essential oil is previously extracted from lavender stoechade. Indeed, the inventors observed that the antibacterial action was particularly effective when the non-evaporated fraction of the EO according to the invention is transformed from an EO extracted from compact oregano or lavender stoechade, the results being even superior with lavender stoechade.
    Preferably, the non-evaporated fraction of EO according to the invention is transformed from an essential oil which is previously extracted from the lavender stoechade, the transformation comprising an evaporation for a period of between 24 and 96 h, under a pressure of between 25 and 75 mbar and at a temperature between 40 and 60 ° C. The inventors have, in fact, observed that the antibacterial action was particularly improved with such a non-evaporated fraction of EO according to the invention.
    Another object of the invention is also a combination comprising an essential oil fraction according to the invention and a second essential oil which has or has not been transformed by the process according to the invention.
    Another object of the invention is also a combination comprising an essential oil fraction according to the invention and at least one antifungal. The antifungal can be, for example, nystatin and fluconazole. The inventors observed an improved combinatorial activity, namely a decrease in the MIC of the association of the antifungal with the non-evaporated fraction of EO according to the invention, compared with the MIC of the antifungal alone.
    Another aspect of the invention is a combination comprising an essential oil fraction according to the invention and at least one antibiotic.
    Preferably, the antibiotic is selected from the group consisting of beta-lactams, tetracyclines, aminoglycosides, phosphonic acid antibiotics, macrolides, quinolones, etc. and mixtures thereof.
    It was observed that the combinatorial activity is improved, that is to say that a decrease in the MIC of the association of an antibiotic with the non-evaporated fraction of EO according to the invention is observed, by compared to the MIC of the antibiotic alone.
    Preferably, the essential oil is first extracted from the lavender stoechade and the antibiotic is a penicillin. The antibacterial effect is particularly effective when the non-evaporated fraction of the invention is obtained from the lavender stoechade and is combined with a penicillin.
    The present invention also relates to the use of the fraction and the combinations according to the invention as a medicament.
    In the context of the present invention, the fraction and the combinations according to the invention can also be used in cosmetics or can relate to the field of human or veterinary medicine.
    The present invention also relates to the use of the fraction and the combinations according to the invention in the prevention or treatment of infectious diseases of bacterial or fungal origin.
    Preferably, the bacterium causing the infectious disease is selected from the group consisting of the Staphylococcaceae family (eg: Staphylococcus aureus), of the Enterobacteriaceae family (eg: Escherichia coli, Enterobacter aerogenes and Klebsiella pneumoniae), of the family Pseudomonadaceae (ex: Pseudomonas aeruginosa), of the Mycobacteriaceae family (ex: Mycobacterium bovis), of the Enterococcaceae family (ex: Enterococcus faecalis), of the Helicobacteriaceae family (ex: Helicobacter pylori), of the Streptococcaceae family (ex: Streptococcaceae (ex: mutans), of the Moraxellaceae family (eg Acinetobacter baumannii), of the Clostridiaceae family (eg: Clostridium difficile), of the Spirochaetaceae family (eg: Borrelia garinii) and their mixtures. Preferably, the fungus causing the infectious disease is Candida albicans. According to a preferred embodiment of the invention, the essential oil is previously extracted from the lavender stoechade and the bacterium is S. aureus. These and other embodiments of the present invention are set out in the appended claims. Examples The invention will now be described in more detail in the following examples which describe non-limiting embodiments of various aspects of the present invention.
    1. Process for transforming essential oils (ET) Commercial EOs (Pranarom} of Ajwain (AW), exotic basil (BE), German chamomile (CA), Chinese cinnamon (CC), leaf coriander ( CF), clove (GF), lemongrass (LG), lavender stoechade (LS), compact oregano (OC) and palmarosa (PM) were transformed according to the process of the invention. the EOs were prepared by adding 0.5 ml of chloroform to 200 μL of EO. The tubes were then placed in a Syncore® evaporator (Büchi} allowing controlled evaporation of 96 samples for a defined time. samples was carried out at a pressure of 60 mbar, a temperature of 40 ° C and under agitation of 250 rotations / minute.
    2. Evolution of the evaporation of EOs transformed as a function of time The evaporation of EOs transformed according to the method of the invention as described above, as a function of the evaporation time was measured and analyzed by gas chromatography. The percentage of evaporation of the samples was measured after an evaporation of 3 h (T1), 18 h (T2), 24 h (T3), 48 h
    (T4) and 72 h (T5). The results, expressed in percentages of evaporation, are shown in Tables 1 (for the least volatile EO) and 2 (for the most volatile EO). Table 1: ee PE -
    ABB CC 1.4 2.8 3.4 4.3 5.1 GF 0.7 1.3 1.8 2.8 3.3 LG 0.8 4.9 6.1 9.6 10.9 PM 0.8 1.8 2.1 3.2 3.5 Legend: the results are expressed as evaporation percentages Table 2: ee U - AW 80 BO 38 ABB SA BE 2.4 6.2 7.6 13.6 18.4 CF 5.4 9.9 12.8 18.3 22.9 LS 7.1 18.7 23.9 41.5 51.3 oC 6.5 15.3 15.8 24.4 27, 4 Legend: the results expressed as percentages of evaporation
    3. Specific and combinatorial activities of non-evaporated EO fractions transformed according to the process of the invention The inherent activity of EO transformed according to the process of the invention (HE-T) with an evaporation of 3 h (T1), 18 h (T2), 24 h (T3), 48 h (T4) and 72 h (T5) was compared with the specific activity of the corresponding commercial HE not transformed according to the method of the invention (HE- VS). The evaporation percentages of each EO tested as a function of the evaporation time are presented in Tables 1 and 2 above. To do this, the stock solutions of HE (HE-C and HE-T) were diluted beforehand in DMSO, - at a rate of 10 uL of HE in 300 uL of DMSO. They were shaken and stored at room temperature, protected from light, in autoclaved glass tubes with screw caps. The specific activity of the EOs was measured by the micro-dilution method in a 96-well plate, so as to obtain the MIC, a value at which a solution inhibits bacterial growth. The bacterial strains treated are S. aureus LMG 15975 methicillin-resistant staphylococcus aureus, here called MRSA +), E. coli LMG 8223, E. coli LMG 15862, P. aeruginosa LMG 6395, S. aureus LMG 8064, S. aureus LMG 16217 (methicillin-resistant Staphylococcus aureus, here called MRSA ++), E. faecalis LMG 8222, K. pneumoniae LMG 20218 and E. aerogenes LMG 2094. Inocula of the bacterial strains were prepared by placing colonies of 18- 24 hours of the strains in suspension in sterile physiological solution (0.85% NaCl). These inocula were then adjusted and diluted so as to obtain a final concentration of 5 x 105 CFU / mL. Regarding the solutions to be tested, 300 μL of the stock solutions of EO (diluted in DMSO) were added to 4.7 mL of culture medium (for example to Mueller Hinton Broth), so as to obtain a solution of EO of 2 mg / mL which is then diluted in series by two in multi-well plates. The final percentage of DMSO in the wells is less than 5%. After inoculation, the multiwell plates were incubated 18-24 h at 37 ° C and the presence of bacteria was visualized by the addition of methyltetrazolium (MTT).
    Combinatorial activity makes it possible to determine whether HE or HE-T inhibits bacterial growth at a so-called sub-MIC concentration, that is to say at a concentration at which HE has no activity. own. The sub-MIC concentration of an EO is equal to a minimum of two MICs (serial dilutions by two) below which the EO is active (self-activity). For example, if the MIC for a given HE is 500 ug / mL, the sub-MIC tested will be a minimum of 125 ug / mL. The sub-MIC values are listed in the HE suc column.
    The combinatorial activity of EO transformed according to the method of the invention with an evaporation of 24 h (HE-T3) and 72 h (HE-T5) was compared with the combinatorial activity of the corresponding commercial EO not transformed according to the method of the invention (HE-C). The same microdilution method that was used to determine clean antibacterial activity was used to determine combinatorial activity. The antibiotics tested in combination with EO transformed or not are amoxicillin (AMOX), penicillin G (PG), penicillin V (PV), cefotaxime (CEFO), gentamicin (GENTA), tetracycline (TETRA) , doxycycline (DOXY), ampicillin (AMPI) and fosfomycin (FOSFO). The bacterial types treated are S. aureus LMG 15975 (MRSA +), S. aureus 16217 (MRSA ++), E. faecalis LMG 8222, E. coli LMG 15862, P. aeruginosa LMG 6395, K. pneumoniae LMG 20218 and E. aerogenes LMG 2094. The difference lies in the fact that it is the antibiotics which have been diluted in series by 2. The EOs, at their sub-MIC concentration, were then added, and the solutions were inoculated with the aforementioned bacterial strains.
    Results The results concerning the intrinsic activity are expressed in ug / ml and indicate the MIC of HEV - whether or not it is transformed by the method according to the invention. The results concerning the combinatorial activity are also expressed in ug / ml and indicate the sub-MIC values of HE, alone or in combination with the antibiotic, whether or not transformed by the method according to the invention.
    All in vitro tests are performed at least in triplicate on at least 3 different samples of an HE-T. Table 3 shows the results of the specific and combinatorial activity in association with the PV of the HE-T according to the invention of AW, of LS and of OC on the strain S. aureus LMG 15975. The antibiotic is penicillin V (PV) whose MIC on this strain is 4 µg / ml. Table 3: Staphylococcus aureus LMG 15975
    PE CMI: PV / HE (ug / ml) HE sub-cmi + PV we es [a | awTs [524 (250 1625 006 OO | me Je pm [ee | ua [a5 [me [eo ce 10 1e es es In the case of ajowan (AW), 50% of the least volatile constituents are present in the HE-T after 72 hours of evaporation This transformation, called AW-T5, slightly increases the specific activity of ajwain which goes from a MIC of 500 ug / ml to a MIC of 250 ug / ml. , untransformed ajwain (AW-C) increased the activity of penicillin V by decreasing its MIC from 4 ug / ml (PV only) to 0.5 ug / ml (PV + AW-C to 125 ug / ml). The combinatorial effect is all the more effective with the HE-T of AW. Combined with the HE-T3 (24h of evaporation} and T5 (72h of evaporation), the MIC of penicillin V decreases 0.125 µg / ml and 0.06 µg / ml, respectively, relative to the MIC of penicillin V alone which is 4 µg / ml.
    In the case of lavender stoechade (LS), the evaporation percentages are similar to those of ajwain, namely that at 72 hours (LS-T5) an evaporation of about 50% of the most compounds is also achieved. volatile. In proper activity, the MIC of LS-C which was greater than 1000 ug / ml decreases gradually until reaching 500 ug / ml at 72 hours of evaporation (LS-T5). In combinatorial activity, HE-T5 increases the activity of penicillin V: the MIC of penicillin V which alone is active at 4 μg / ml decreases to 0.06 μg / ml when it is combined with LS-C and LS-T3 and 0.03 µg / ml when combined with HE-T5.
    In the case of oregano (OC), the transformations cause evaporation of the most volatile compounds of about 16% at 24 hours (OC-T3) and of about 27% at 72 hours (OC-T5). OC's direct HE-T activity is maintained at 250 µg / ml throughout transformations (OC-T3 and OC-T5). In combinatorial activity with penicillin V, the HE-T resulting from the transformation strongly reduced the MICs compared to that of commercial oregano (OC-C): the MIC of penicillin V alone is 4 μg / ml and decreases to 0.25 µg / ml when combined with OC-C. The MIC of penicillin V gradually decreases to 0.125 µg / ml when combined with OC-T3 extract and reaches the concentration of 0.03 µg / ml when combined with OC-T5.
    In all three cases, the combination of HE-T5 (AW-T5, LS-T5 and OC-T5) with penicillin V makes it possible to go down to concentration ranges close to those obtained on the MSSA strain LMG 8064 (Staphylococcus aureus methicillin sensitive) with an MIC of PV of 0.015 µg / ml. The HE-T according to the invention therefore have the capacity to restore the activity of penicillin V on a strain that has become resistant.
    In conclusion, the transformation process according to the invention makes it possible to obtain HE-T obtained from essential oils which have an increased antibacterial activity whether in its own activity when the HE-T is used alone and / or in activity. combinatorial when HE-T is combined with an antibiotic. This last case is all the more interesting because it would make it possible to reduce the doses of antibiotics to be administered by combining them with an HE-T whose dose is not active per se.
    Table 4 shows the results of the combinatorial activity in association with AMOX, PV and PG of HE-T according to the invention of LS on the S. aureus LMG strain 16217. The antibiotics are amoxicillin whose MIC on this strain is 64 ug / ml, penicillin G whose MIC on this strain is 64 ug / ml and penicillin V whose MIC on this strain is 64 ug / ml.
    Table 4: Reference strain: Staphylococcus aureus LMG 16217 HE sub-combinatorial% evaporation PCM (pg / ml) HE sub-cmi + AB (Hg / ml) AMOX THE ECO CE PV THE ECO CE PG
    THE CE ECO Table 5 shows the results of the specific activity of the HE-T according to the invention of AW, CC, LG, OC and PM on the strain Escherichia coli LMG 15862. Table 5:
    Reference strain: Escherichia coli LMG 15862% evaporation TUT TE (ug / ml) Ar Ar Awa ee TO
    In all cases (AW, CC, LG, OC and PM), the inherent activity increases when the EOs are transformed according to the process of the invention compared to the untransformed EOs (HE-C). In fact, a general decrease in the MIC is observed when the E. coli LMG 15862 strain is treated with the different (AW, CC, LG, OC and PM) HE-T transformed according to the method of the invention.
    权利要求:
    Claims (15)
    [1]
    1. A process for transforming an essential oil comprising: - providing an essential oil previously extracted; - evaporate a fraction between 7 and 90% of the essential oil; and - obtain a transformed essential oil comprising the recovery of the non-evaporated fraction of the essential oil, characterized in that the evaporation is carried out for at least 2 h, under a pressure less than or equal to 500 mbar and at a temperature between 40 and 100 ° C.
    [2]
    2. The transformation process according to claim 1, characterized in that the evaporation is between 20 and 75%, still preferably between 20 and 50%, even more preferably between 30 and 50%, even more preferably. about 45% of the essential oil.
    [3]
    3. The transformation process according to claim 1 or 2, characterized in that the evaporation is carried out for a period of between 18 and 96 h, even more preferably between 24 and 96 h, even more preferably for a period of d 'about 72 h.
    [4]
    4. The transformation process according to any one of the preceding claims, characterized in that the evaporation is carried out under a pressure less than or equal to 300 mbar, preferably less than or equal to 150 mbar, more preferably less than or equal to 100 mbar, even more preferably between 25 and 75 mbar, even more preferably around 60 mbar.
    [5]
    - 5. The transformation process according to any one of the preceding claims, characterized in that the evaporation is carried out at a temperature between 40 and 60 ° C, more preferably at a temperature of about 40 ° C.
    [6]
    6. The transformation process according to any one of the preceding claims, characterized in that the essential oil is previously extracted from the lavender stoechade or compact oregano, preferably the essential oil is previously extracted from the lavender stoechade .
    [7]
    7. The transformation process according to any one of the preceding claims, characterized in that the essential oil is first extracted from the lavender stoechade and in that the evaporation is carried out for a period of between 24 and 96 h, under a pressure between 25 and 75 mbar and at a temperature between 40 and 60 ° C.
    [8]
    8. A fraction of essential oil obtainable by the transformation process according to any one of claims 1 to 7.
    [9]
    9. A combination comprising an essential oil fraction according to claim 8 and a second essential oil which has or has not been transformed by the process according to any one of claims
    137.
    [10]
    10. A combination comprising an essential oil fraction according to claim 8 and at least one antifungal.
    [11]
    11. A combination comprising an essential oil fraction according to claim 8 and at least one antibiotic.
    [12]
    12. The combination according to claim 11, characterized in that the essential oil is previously extracted from the lavender stoechade and the antibiotic is a penicillin.
    [13]
    13. The essential oil fraction of claim 8 or the combination of claim 10 or the combination of claim 11 or 12, for use as a medicament.
    [14]
    14. The essential oil fraction according to claim 8 or the combination according to claim 10 or the combination according to claim 11 or 12, for use in the prevention or treatment of infectious diseases of bacterial or fungal origin.
    [15]
    15. The essential oil fraction or the combination for use according to claim 14, - characterized in that the essential oil is previously extracted from the lavender stoechade and the bacteria is S. aureus.
    类似技术:
    公开号 | 公开日 | 专利标题
    Sharifi‐Rad et al.2018|Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applications
    Nuzhat et al.2014|Antifungal investigations on plant essential oils. A review
    Adrar et al.2016|Antioxidant and antibacterial activities of Thymus numidicus and Salvia officinalis essential oils alone or in combination
    Saraswathi et al.2011|Phytopharmacological importance of Pelargonium species
    WO2005087244A1|2005-09-22|Antimicrobial composition
    Elshafie et al.2016|An in vitro attempt for controlling severe phytopathogens and human pathogens using essential oils from mediterranean plants of genus schinus
    US7429396B2|2008-09-30|Antifungal composition, its fungicidal effect on pathogenic dermatophytes, and process for inhibiting growth of fungi
    Neves et al.2018|Pharmacological and biotechnological advances with Rosmarinus officinalis L
    Atef et al.2015|Chemical composition and antimicrobial activity of essential oils in Xerophytic plant Cotula cinerea Del | during two stages of development: flowering and fruiting
    Girardot et al.2016|Natural sources as innovative solutions against fungal biofilms
    JP2005023000A|2005-01-27|Anti-bacterial agent and method for producing the same, and food preparation and antiseptic
    Getahun et al.2019|The genus Laggera |–ethnobotanical and ethnopharmacological information, chemical composition as well as biological activities of its essential oils and extracts: a review
    Asgarpanah et al.2015|An overview on phytopharmacology of Pelargonium graveolens L.
    Srinivasan et al.2019|Phytochemical, antioxidant, antimicrobial and antiproliferative potential of Elaeagnus indica
    BE1027762B1|2021-10-11|PROCESS FOR TRANSFORMATION OF AN ESSENTIAL OIL
    Chouia et al.2018|Antibacterial activity and DPPH• radical scavenging of differents metabolites extracted from two plants: essential oil from | and flavonoids from flowers and leaves of |
    Mancarz et al.2016|Antimicrobial and antioxidant activity of the leaves, bark and stems of Liquidambar styraciflua L.|
    WO2002062362A2|2002-08-15|Antiviral and antibacterial composition
    WO2019086602A1|2019-05-09|Particular extract from perfume plants, aromatic plants and medicinal plants, method for obtaining said extract, compositions containing same and uses thereof
    Mazandarani et al.2015|Autecology essential oil composition, antibacterial, anti candidacies and ethnopharmacological survey of Ferula gummosa L. as anti infection to treat of vaginal infections in traditional medicine of Razavi Khorasan province |
    Singh et al.2020|Antimicrobial Activity of Extracts of Bark of Cinnamomum cassia and Cinnamomum zeylanicum
    FR2854076A1|2004-10-29|Essential oil from Monarda fistulosa, useful as antiseptic, antibacterial, antifungal and anti-acne agent, in human or veterinary medicine or cosmetics
    Avila et al.2013|Antimicrobial activity of Caesalpinia melanadenia | Standl |
    Kačániová et al.2020|Antimicrobial potential of different medicinal plants against food industry pathogens.
    FIKRI et al.2020|Structure activity modeling of essential oils compounds and plant secondary metabolites: a Mini review of Antimicrobial Activity
    同族专利:
    公开号 | 公开日
    WO2021110915A1|2021-06-10|
    BE1027762A1|2021-06-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2001015680A1|1999-09-01|2001-03-08|Van Beek Global/Ninkov L.L.C.|Composition for treatment of infections of humans and animals|
    FR2918571A1|2007-07-10|2009-01-16|Aroma Technologies Soc Par Act|ANTIBIOTIC COMPOSITIONS BASED ON ESSENTIAL OILS PROPHYLAXIS AND TREATMENT OF NOSOCOMIAL INFECTIONS|
    WO2012023146A1|2010-08-16|2012-02-23|Benny Antony|A pharmaceutical composition of reformulated turmeric extract and a method thereof|
    WO2012114201A1|2011-02-25|2012-08-30|Aroma Technologies|Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic|
    CN109679767A|2019-01-28|2019-04-26|江西中医药大学|A method of it is comprehensive from HERBA ELSHOLTZIAE herb to extract volatile oil|
    WO2006120494A1|2005-05-13|2006-11-16|Advanced Scientific Developements|Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol|
    DE202007015195U1|2007-11-02|2008-08-14|Universitätsklinikum Freiburg|Preparations containing coriander oil fractions and their use for the preparation of a medicament or cosmetic agent|
    EP3463479A2|2016-06-02|2019-04-10|Advanced Scientific Developements|Pharmaceutical formulation comprising cineol and amoxicillin|
    法律状态:
    2021-10-27| FG| Patent granted|Effective date: 20211011 |
    优先权:
    申请号 | 申请日 | 专利标题
    EP19306569|2019-12-04|
    [返回顶部]